We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dummy Cell Receptor Reduces Tumor Size and Spread

By Biotechdaily staff writers
Posted on 20 May 2002
An animal study had found that a specially designed cell receptor may reduce cancer death rates by soaking up excess tumor-produced chemicals like a sponge. More...
The study, led by researchers at the University of California, Irvine (UCI, USA), was reported in the January 2002 issue of Molecular Cancer Therapeutics.

Using human pancreatic cancer cells in mice, the researchers found that the binding of growth factors to dummy receptors--those incapable of sending signals to cells-- had the effect of sharply reducing tumor size and decreasing the spread of cancer cells to other parts of the body. The dummy receptors acted like a sponge, mopping up excess levels of the growth factor TGF-beta, found in cancer cells. Mice with the dummy receptor for TGF-beta showed a 72% reduction in tumor growth one week after injection compared to mice without the receptor. After 50 days, mice with the receptor had an average tumor cell volume of less than 50 cubic mm, while mice without the dummy receptor had tumor cell volume of about 300 cubic mm.

Also, when parts of the tumor cells were injected into mice known to show metastatic spreading, those mice with the dummy receptor showed far less evidence of metastasis than mice without the receptor. In a similar method, dummy receptors for tumor necrosis factor (TNF) are being used clinically to reduce excessive inflammation in arthritis patients.

"This study confirms our earlier findings suggesting that increased levels of TGF-beta make pancreatic cancer cells grow more aggressively,” said Dr. Murray Core, professor of medicine and chief of endocrinology at UCI Medical Center. "We were originally surprised to see these high levels of TGF-beta expressed in pancreatic cancer, since it generally inhibits cell growth. This new role for TGF-beta may lead us to design targeted therapies against pancreatic and other cancers marked by high levels of this growth factor.”

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
POC Immunoassay Analyzer
Procise DX
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.